Patent 11873336 was granted and assigned to TeneoBio on January, 2024 by the United States Patent and Trademark Office.
Anti-CD22 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD22.